Literature DB >> 10798054

Venous thromboembolism.

R Gera1, R Kulkarni.   

Abstract

Incidence of venous thromboembolism (VTE) in children is rapidly rising. Frequent use of central venous lines (CVLs) in children with a variety of disease processes has contributed to increased incidence of VTE. In addition, increased detection of VTE has been possible due to the availability of sensitive imaging studies such as Color Duplex/Doppler ultrasound, lineogram and venogram. Heightened awareness of congenital prethrombotic disorders may help identify children at higher risk of thrombosis. Anticoagulation with heparin, low molecular weight heparin (LMWH) and oral anticoagulant such as warfarin are used for the treatment of VTE. Thrombolytic therapy may be indicated in some cases. Clinical presentation, management and pathogenesis including role of congenital prethrombotic disorders in pediatric VTE are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10798054     DOI: 10.1007/bf02761196

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  21 in total

Review 1.  Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years.

Authors:  W Zenz; F Arlt; S Sodia; A Berghold
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

Review 2.  Thrombolytic therapy in pediatric patients: a comprehensive review of the literature.

Authors:  M Leaker; M P Massicotte; L A Brooker; M Andrew
Journal:  Thromb Haemost       Date:  1996-08       Impact factor: 5.249

Review 3.  Disorders of hemostasis in childhood: risk factors for venous thromboembolism.

Authors:  M J Manco-Johnson
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

Review 4.  Antithrombotic therapy in children.

Authors:  A D Michelson; E Bovill; M Andrew
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

5.  Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.

Authors:  L Shen; B Dahlbäck
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

6.  Heparin-induced thrombocytopenia in a child.

Authors:  C Potter; J C Gill; J P Scott; J G McFarland
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

Review 7.  Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.

Authors:  B Dahlbäck
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

8.  Heparin therapy in pediatric patients: a prospective cohort study.

Authors:  M Andrew; V Marzinotto; P Massicotte; V Blanchette; J Ginsberg; P Brill-Edwards; P Burrows; L Benson; W Williams; M David
Journal:  Pediatr Res       Date:  1994-01       Impact factor: 3.756

9.  Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE.

Authors:  M Andrew; M David; M Adams; K Ali; R Anderson; D Barnard; M Bernstein; L Brisson; B Cairney; D DeSai
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.